Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 6/20 | 0.59 |
| ▸ | PPP5C | P53041 | 2/20 | 0.59 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | PPM1B | O75688 | 3/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11885821 | 1.00 | TFPI2 (0.59) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377824 | 1.00 | TFPI2 (0.59) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL20459539 | 0.88 | TFPI2 (0.56) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377945 | 0.85 | TFPI2 (0.43) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL18073235 | 0.82 | TFPI2 (0.59) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377845 | 0.82 | TFPI2 (0.62) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL16731300 | 0.82 | TFPI2 (0.62) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL9880171 | 0.81 | PPP5C (0.39) | TFPI2PPP5CPPP2CANPY4RTSHR | |
| SCHEMBL18235540 | 0.81 | TFPI2 (0.60) | TFPI2PPP5CPPP2CANPY4RPPM1B | |
| SCHEMBL26377839 | 0.81 | TFPI2 (0.60) | TFPI2PPP5CPPP2CANPY4RPPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2870161-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY INC (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010014254-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | OAT, OGG1, OTC | TFPI2 4233/4885PPP5C 1913/4885PPP2CA 770/4885 |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPP3CA | TFPI2 912/4885PPP5C 7/4885PPP2CA 1/4885 |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | TFPI2 1195/4885PPP5C 8/4885PPP2CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.